# Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective

**Authors:** Yan Teng, Yong Yu, Sujing Li, Youming Huang, Danfeng Xu, Xiaohua Tao, Yibin Fan

PMC · DOI: 10.3389/fpubh.2021.666528 · Frontiers in Public Health · 2021-07-22

## TL;DR

This paper explores how ultraviolet radiation contributes to the development of basal cell carcinoma, focusing on environmental factors and biological mechanisms.

## Contribution

The paper reviews recent advances in understanding UVR-induced BCC pathogenesis from genetic and inflammatory perspectives.

## Key findings

- UVR, especially UVB, is a major environmental risk factor for basal cell carcinoma.
- UVR causes DNA damage and activates oncogenes while inactivating tumor suppressor genes.
- Inflammatory responses in the tumor microenvironment play a key role in skin tumorigenesis.

## Abstract

Ultraviolet radiation (UVR) is a known carcinogen participated for the development of skin cancers. Solar UVR exposure, particularly ultraviolet B (UVB), is the mostly significant environmental risk factor for the occurrence and progress of basal cell carcinoma(BCC). Both cumulative and intermittent high-grade UVR exposure could promote the uncontrolled replication of skin cells. There are also exsiting other contributing environmental factors that combine with the UVR exposure to promote the development of BCC. DNA damage in formation of skin cancers is considered to be a result of UVR toxicity. It is UVR that could activate a series of oncogenes simultaneously inactivating tumor suppressor genes and aberrant proliferation and survival of keratinocytes that repair these damages. Furthermore, mounting evidence demonstrates that inflammatory responses of immune cells in the tumor microenvironment plays crucial role in the skin tumorigenesis as well. In this chapter, we will follow the function of UVR in the onset and development of BCC. We describe the factors that influence BCC induced by UVR, and also review the recent advances of pathogenesis of BCC induced by UVR from the genetic and inflammatory aspects.

## Linked entities

- **Diseases:** basal cell carcinoma (MONDO:0005341)

## Full-text entities

- **Genes:** PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, GLI2 (GLI family zinc finger 2) [NCBI Gene 2736] {aka CJS, HPE9, PHS2, THP1, THP2}, PTCH1 (patched 1) [NCBI Gene 5727] {aka BCNS, BCNS1, NBCCS, PTC, PTC1, PTCH}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CHUK (component of inhibitor of nuclear factor kappa B kinase complex) [NCBI Gene 1147] {aka BPS2, IKBKA, IKK-1, IKK-alpha, IKK1, IKKA}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Tert (telomerase reverse transcriptase) [NCBI Gene 21752] {aka EST2, TCS1, TP2, TR, TRT}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Dph3 (diphthamine biosynthesis 3) [NCBI Gene 105638] {aka DELGIP1, DelgipP1, Desr1, KTI11, Zcsl2}, PTCH2 (patched 2) [NCBI Gene 8643] {aka PTC2, SLC65B2}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, IL12A (interleukin 12A) [NCBI Gene 3592] {aka CLMF, IL-12A, NFSK, NKSF1, P35}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, SUFU (SUFU negative regulator of hedgehog signaling) [NCBI Gene 51684] {aka BCNS2, JBTS32, PRO1280, SUFUH, SUFUXL}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, ADAM12 (ADAM metallopeptidase domain 12) [NCBI Gene 8038] {aka ADAM12-OT1, CAR10, MCMP, MCMPMltna, MLTN, MLTNA}, ATP2A3 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3) [NCBI Gene 489] {aka SERCA3}, GLI1 (GLI family zinc finger 1) [NCBI Gene 2735] {aka GLI, PAPA8, PPD1}, Dph1 (diphthamide biosynthesis 1) [NCBI Gene 116905] {aka 2310011M22Rik, 4930488F09Rik, Dph2l1, Ovca1}, VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, Eef2 (eukaryotic translation elongation factor 2) [NCBI Gene 13629] {aka Ef-2}, Oxnad1 (oxidoreductase NAD-binding domain containing 1) [NCBI Gene 218885] {aka 2410002F01Rik}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}
- **Diseases:** colon, breast, prostate cancers (MESH:D001943), toxicity (MESH:D064420), death (MESH:D003643), phototoxic cutaneous disorders (MESH:D017484), SCC (MESH:D002294), inflammatory skin diseases (MESH:D012871), metastatic (MESH:D000092182), immune system disorders (MESH:D007154), NMSCs (MESH:D012878), basal cell carcinoma/cancer (MESH:D018295), bladder, lung, and kidney cancer (MESH:D007680), lung cancer (MESH:D008175), psoriasis (MESH:D011565), erythema (MESH:D004890), overweight (MESH:D050177), Cancer (MESH:D009369), edematous (MESH:D004487), pharynx and larynx, esophagus, breast, prostate, pancreatic, and colon cancers (MESH:C537243), skin carcinogenesis (MESH:D063646), metastasis (MESH:D009362), carcinogenicity (MESH:D011230), BCC (MESH:D002280), glioma (MESH:D005910), chronic cutaneous inflammatory diseases (MESH:D002908), obesity (MESH:D009765), aggressive (MESH:D010554), AK (MESH:D055623), head/neck lesions (MESH:D006258), Chronic inflammation (MESH:D007249), MM (MESH:D008545), sunburn (MESH:D013471)
- **Chemicals:** Vitamin D (MESH:D014807), diphthamide (MESH:C027527), naproxen (MESH:D009288), PG (MESH:D011453), polonium-218 (MESH:C000615143), Alcohol (MESH:D000438), Tetracycline (MESH:D013752), celecoxib (MESH:D000068579), Furocoumarins (MESH:D011564), water (MESH:D014867), 25-OH vitamin D3 (-), radium-226 (MESH:C000615152), caffeine (MESH:D002110), Psoralen (MESH:D005363), Arsenic (MESH:D001151), Radon-222 (MESH:C000615148), acetaldehyde (MESH:D000079), Radon (MESH:D011886), 25-OH D3 (MESH:D002112), Imiquimod (MESH:D000077271), histidine (MESH:D006639), indomethacin (MESH:D007213)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Citrus (genus) [taxon 2706], Dipturus trachyderma (ray, species) [taxon 255564]
- **Mutations:** C to T, CC to TT, W535L

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8339433/full.md

## References

162 references — full list in the complete paper: https://tomesphere.com/paper/PMC8339433/full.md

---
Source: https://tomesphere.com/paper/PMC8339433